The Aducanumab Aftermath: The Industry
How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug?
Read MoreMonth: June 2021
Charting the Uneven Progress in Medical School Diversity
Samantha Artiga discusses research showing how several racial and ethnic groups continue to be underrepresented in U.S. medical schools.
Read More
The Aducanumab Aftermath: The Payer
A costly new Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.
Read More
“The Aducanumab Aftermath: The Doctor Transcript”
‘The Aducanumab Aftermath: The Doctor’ Transcript June 22, 2021 Note: This transcript has been created with a combination of machine ears and human eyes. There may be small differences between this document and the audio version, which is one of many reasons we encourage you to listen to the episode! Listen in Apple Podcasts Listen on…
Read More
The Aducanumab Aftermath: The Doctor
One doctor grapples with questions about a controversial new Alzheimer’s drug’s safety and efficacy.
Read More
Babies, Boats & Abstracts: An Insider’s Guide to Health Policy Conferences
Health economist Kosali Simon shares conference tips, stories and abstracts she’s excited for at AcademyHealth and ASHEcon.
Read More
How Can Health Policy Researchers Measure Structural Racism?
Katy Backes Kozhimannil explores a review of how the impacts of structural racism have been studied in reproductive health.
Read More
Drilling Into a Dentist’s COVID Roller Coaster Ride
From the fear of shutting down to the exhaustion of reopening and the missed appointments in between.
Read More
What NASCAR Can Teach Us About Pollution and Social Determinants of Health
Kosali Simon breaks down research that uses NASCAR’s switch to unleaded gas to explore the impact of pollution on kids’ cognitive development.
Read More